A small pilot study by a team of French researchers has established the long-term benefits of upfront triple combination therapy among patients with severe pulmonary arterial hypertension (PAH) The U.S. National Library of Medicine (NLM) describes pulmonary arterial hypertension as abnormally high blood pressure in the arteries of the lungs that makes…
News
Results released Monday, May 5th from Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey revealed that those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of being diagnosed with disease. Chief among the difficulties experienced among the PH…
Bayer HealthCare, a subsidiary of German-owned corporation, Bayer AG, has just announced that it has registered its therapeutic drug Riociguat for regulatory clearance in Japan. The drug has gone through intensive clinical research and development under Bayer, and is eyeing becoming the next novel treatment of two types of…
Bayer Healthcare recently announced the approval of its novel drug Adempas (riociguat), which has been listed by the Régie de l’assurance malady du Québec (RAMQ), the Québec public formulary, as the one and only treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Québec is the first province to provide Adempas…
It was reported last month that the drug Sildenafil, popularly known as “Viagra,” an erectile dysfunction therapy for men, also revealed efficacy in treating those with pulmonary hypertension. However, for those with the disease who did not respond to sildenafil, a new, alliterative therapy may show promise, specifically for…
There is a basic difference between pulmonary arterial hypertension (PAH) in adults and in children. In the former case, there are a wide range of causes that contribute to development of PAH, including thromoembolism, vascular obstruction, pulmonary insufficiency, alveolar hypoventilation, chronic lung disease, and other associated comorbidities (e.g.: systemic,…
It is commonly known that exercise capacity is impaired in pulmonary arterial hypertension (PAH). Â Thanks to a recent study, researchers were able to test a hypothesis on why this is the case, with the idea that perhaps cardiovascular reserve anomalies are in fact linked with an impaired hemodynamics response…
Pulmonary Arterial Hypertension (PAH) is a frequently encountered complication of Systemic Sclerosis (SSc). PAH is also the leading cause of morbidity and mortality among SSc patients. Despite some progress in new detection methods, standard right heart catheterization still remains the most effective means of diagnosis of PAH with Systemic…
Scientists now believe that uric acid (UA) levels are a significant health consideration for PAH patients, as UA has been demonstrated to be elevated in patients with pulmonary arterial hypertension (PAH) and heart failure. Â Elevated UA levels have been linked with poor patient outcomes. According to recent research published…
Gregory Piazza, MD, clinical instructor in medicine at Harvard Medical School, presented the results of a single-arm, multi center trial that tested the efficacy of the EkoSonic endovascular system. 150 patients, all with proximal pulmonary embolism (PE) and a dilated right ventricle (RV/VL ratio ≥0.9) were examined using ultrasound-delivered,…
When diagnosing and treating diseases and conditions such as Pulmonary Arterial Hypertension, clear, accurate, and reliable imaging of the heart and surrounding tissues is essential for achieving the best outcomes for patients. A new imaging technology for PAH and other related indications is currently moving its way through testing, and…
A group of researchers led by Dr. Sophie Grigoriadis, MD, PhD, head of the women’s mood and anxiety clinic at Sunnybrook Health Sciences Center in Toronto, Canada, and associate professor of psychiatry at the University of Toronto, performed a total of 7 meta-analyses based on available data resources, determining…
